Iron and the anemia of chronic disease: Vindication for the non-essential role of iron supplementation

Oncology

Volumn 25, Issue 5, 2011, Pages

  Spivak, Jerry L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1; IRON; RECOMBINANT ERYTHROPOIETIN;

BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; HORMONE ACTION; HUMAN; INFECTION; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON THERAPY; KIDNEY FAILURE; MEDICAL LITERATURE; NOTE; ONCOLOGY; PATHOGENESIS; VASCULARIZATION;

EID: 79956204575     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (1)

1. Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncology. 2011;29:97-105.